Adalank
N-Acetyl Selank Amidate | Enhanced Tuftsin Analog
Adalank (N-Acetyl Selank Amidate) is an enhanced synthetic derivative of Selank peptide, featuring N-terminal acetylation and C-terminal amidation for superior stability and blood-brain barrier penetration. Developed from the immunomodulatory peptide tuftsin, it's researched for anxiety reduction, cognitive enhancement, neuroprotection, and stress resilience with improved pharmacokinetic properties compared to the parent compound.
Daily dose
200-500mcg
Frequency
1-2x daily
Cycle length
2-4 weeks
Storage
2-8°C
Key benefits
Potent anxiolytic effects without sedation or dependency, enhanced cognitive function, stress resilience, improved mood, neuroprotection via BDNF upregulation, and immunomodulatory support. Superior stability and extended half-life compared to parent compound Selank.
How it works
Adalank (N-Acetyl Selank Amidate) crosses the blood-brain barrier via enhanced lipophilicity from N-terminal acetylation and C-terminal amidation. It modulates GABAergic neurotransmission for anxiolytic effects, rapidly upregulates BDNF in hippocampus for neuroprotection and cognitive enhancement, influences serotonin metabolism for mood support, and provides immunomodulatory effects through tuftsin-derived mechanisms. Unlike benzodiazepines, it produces no tolerance, dependency, or withdrawal.
Dosage protocols
Goal
Anxiety reduction
Dose
200-300mcg · 1-2x daily
Route
SubQ or intranasal
Goal
Cognitive enhancement
Dose
200-500mcg · 1x daily
Route
SubQ
Goal
Stress management
Dose
200-300mcg · 2-3x daily
Route
Intranasal spray
Goal
Initial trial
Dose
100-200mcg · 1x daily
Route
SubQ or intranasal
Research indications
anxiety
cognitive
neuroprotective
Administration
Interactions
Safety notes
CRITICAL: Experimental peptide with limited direct research on N-Acetyl form
Parent compound Selank has extensive Russian clinical validation
Approved for clinical use in Russia, not FDA-approved in US
Use sterile technique for injections
No tolerance, dependency, or withdrawal unlike benzodiazepines
Start with lower doses to assess individual response
Cycle with 1-2 week breaks to prevent potential tolerance
Not recommended during pregnancy or breastfeeding
Consult healthcare provider before use
Research studies
Selank and BDNF Regulation in Hippocampus (Parent Compound)
Rats | Intranasal administration | BDNF expression measured in vivo
Selank rapidly elevated Brain-Derived Neurotrophic Factor (BDNF) expression in rat hippocampus, confirming involvement of neurotrophin mechanisms in its cognitive and anxiolytic effects.
View study →Peptide Selank Enhances Diazepam Effects in Stress (Parent Compound)
Rats | Combination therapy | Chronic mild stress model
Selank enhanced anxiolytic effects of diazepam while reducing undesirable side effects including memory impairment, sedation, and attention deficits. Demonstrated potential for combination therapy.
View study →Selank and GABAergic Neurotransmission Gene Expression (Parent Compound)
Cells and animals | Gene expression analysis | GABAergic pathways studied
Research demonstrated that Selank affects expression of genes involved in GABAergic neurotransmission, explaining its anxiolytic mechanism comparable to benzodiazepines but without dependency risk.
View study →Tuftsin Analog Selank and Inflammation-Related Gene Expression (Parent Compound)
Mice | 100 mcg/kg i.p. | Gene expression analysis at 6 and 24 hours
Analysis revealed significant changes in expression of 34 inflammation-related genes following Selank administration, demonstrating broad immunomodulatory and anti-inflammatory properties.
View study →Immunomodulatory Effects of Selank in Anxiety Patients (Parent Compound)
Humans | 14 days treatment | Cytokine balance measured
Clinical study found changes in Th1/Th2 cytokine balance in patients with GAD and neurasthenia receiving Selank, suggesting dual anxiolytic and immunomodulatory therapeutic mechanisms.
View study →Selank for Generalized Anxiety Disorder - Non-inferiority Trial (Parent Compound)
Humans | 62 patients with GAD | 2700 mcg/day intranasal | 14 days
Parent compound Selank demonstrated anxiolytic effects similar to medazepam (benzodiazepine) but with additional antiasthenic and psychostimulant effects. 40% of patients showed rapid response with symptom reduction within 1-3 days, while 60% responded gradually over 14 days.
View study →